跳至主要内容
临床试验/NCT06906978
NCT06906978尚未招募不适用

Single Cell Acute Leukemia Analysis

Assistance Publique Hopitaux De Marseille0 个研究点目标入组 40 人开始时间: 2025年7月31日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
40
主要终点
percentage of leukemic blasts coexpressing P-glycoprotein (PGP)-Multidrug resistance-related protein (MRP)+ Glutathione S-transferase (GST)+ anti- B-cell Lymphoma 2 (BLC2)

研究概览

简要总结

Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. As a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. This hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. The current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patient
  • Patient who has received information about the study and has not expressed opposition,
  • Patients who are beneficiaries of a social security plan,
  • Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.

排除标准

  • Persons who do not understand the French language if there is no translator available to translate for them.
  • Absence of circulating blastosis.

结局指标

主要结局

percentage of leukemic blasts coexpressing P-glycoprotein (PGP)-Multidrug resistance-related protein (MRP)+ Glutathione S-transferase (GST)+ anti- B-cell Lymphoma 2 (BLC2)

时间窗: 36 months

Preliminary in vitro data show that the percentage of blasts coexpressing PGP+MRP+GST+BCL2 is 15% after in vitro chemotherapy. To verify these data in relapsed/refractory patients, the investigators will evaluate the percentage of patients with in vivo leukemic blasts coexpressing PGP+MRP+GST+BCL2 at \>15% post-chemotherapy.

次要结局

  • percentage of P-glycoprotein (PGP)-Multidrug resistance-related protein (MRP)+ Glutathione S-transferase (GST)+ anti- B-cell Lymphoma 2 (BLC2) coexpression in leukemic blasts(36 months)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Single Cell Acute Leukemia Analysis | 临床试验